Treatment with bestatin (the exogenous synthetic inhibitor of metalloproteinases) reduces the activity of metalloproteinase 2 and 12 in the spleen and lung tissues of rats in a model of lipopolysaccharide-induced sepsis - 27/04/24
, Jarosław Piasecki b, Andrzej Borzęcki aAbstract |
Sepsis is caused by an inadequate or dysregulated host response to infection. Enzymes causing cellular degradation are matrix metalloproteinases (MMPs). Lipopolysaccharide (LPS) is used in models of sepsis in laboratory settings
The aim of the study was to measure MMP 2 and 12 concentrations in spleen and lungs in rats in which septic shock was induced by LPS.
The experiment was carried out on 40 male Wistar rats (5 groups of 8):
0. controls
1. administered LPS
2. administered bestatin
3. LPS and bestatin
4.bestatin and after 6 hours LPS
Animals were decapitated. Lungs and spleens were collected. Concentrations of MMP-2 and MMP-12 were determined using immunoenzymatic methods.
Mean (±SD) MMP-2 in the controls was 43.57 ± 20.53 ng/ml in the lungs and 1.7 ± 0.72 ng/ml in the spleen; Group 1: 31.28 ± 13.13 ng/ml, 0.83 ± 0.8 ng/ml; Group 2: 44.24 ± 22.75 ng /ml, 1.01 ± 0.32 ng/ml; Group 3: 35.94 ± 15.13 ng/ml, 0.41 ± 0.03 ng/ml; Group 4:79.42 ± 44.70 ng/ml, 0.45 ± 0.15, respectively.
Mean MMP-12 in controls was 19.79 ± 10.01 ng/ml in lungs and 41.13 ± 15.99 ng/ml in the spleen; Group 1:27.97 ± 15.1 ng/ml; 40.44 ± 11.2 ng/ml; Group 2: 37.93 ± 25.38 ng/ml 41.05 ± 18.08 ng/ml; Group 3: 40.59 ± 11.46 ng/ml, 35.16 ± 12.89 ng/ml; Group 4: 39.4 ± 17.83 ng/ml, 42.04 ± 12.35 ng/ml, respectively.
Conclusions |
1. Bestatin reduces MMP 2 and 12 levels in spleen and lungs.
2. Treatment with bestatin minimizes the effect of LPS.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Bestatin reduces the concentration of metalloproteinases 2 and 12 in the spleen. |
• | Bestatin reduces the concentration of metalloproteinases 2 and 12 in the lung. |
• | Pretreatment with bestatin minimizes the effect of lipopolysaccharide. |
Keywords : Bestatin, Metalloproteinase 2, Metalloproteinase 12
Plan
Vol 174
Article 116480- mai 2024 Retour au numéro
Article précédent
- BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury
- Maria Laura Saiz, Laura Lozano-Chamizo, Aida Bernardo Florez, Marzia Marciello, Paula Diaz-Bulnes, Viviana Corte-Iglesias, Cristian Ruiz Bernet, Raul R. Rodrigues-Diez, Cristina Martin-Martin, Mar Rodriguez-Santamaria, Ivan Fernandez-Vega, Ramon M. Rodriguez, Carmen Diaz-Corte, Beatriz Suarez-Alvarez, Marco Filice, Carlos Lopez-Larrea
- MRGPRB2/X2 and the analogous effects of its agonist and antagonist in DSS-induced colitis in mice
- Karthi Duraisamy, Mukesh Kumar, Abdullah Nawabjan, Emily Kwun Kwan Lo, Ming hui Lin, Benjamin Lefranc, Elsa Bonnafé, Michel Treilhou, Hani El-Nezami, Jérôme Leprince, Billy K.C. Chow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?